Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.915 USD | +5.23% | +42.20% | -13.24% |
12:10pm | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
May. 01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.24% | 268M | |
-1.04% | 104B | |
+6.24% | 97.47B | |
+5.71% | 22.25B | |
-13.32% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.23% | 16.36B | |
+8.58% | 14.39B | |
+39.58% | 12.37B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating